Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
NCT ID NCT01629498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT) or proton (IMPT) radiation therapy along with chemotherapy. The goal is to find the safest highest dose and see if it helps control the tumor longer without causing severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung cancer drug shows promise in keeping tumors at bay after chemo
- New drug combo aims to reboot immune system against lung cancer
- Proton vs. photon: which radiation beats lung cancer best?
- New cocktail for tough lung cancer shows promise in small trial
- New combo aims to outdo chemo for tough lung cancers
- Could PET scans guide radiation to better fight lung cancer?